Keros Therapeutics, Inc.
HealthcareNASDAQ:KROS · NASDAQ Global Market
+$0.10 today
Vol 0.17M · Avg 0.37M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
28.7%
avg -329.2%
ROIC
20.9%
avg -38.6%
ROA
25.7%
avg -29.7%
Analysis
ROE is currently the strongest return metric at 28.7% versus its period average of -329.2%. 3 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Jasbir S. Seehra | President, Chief Executive Officer & Director | $1.11M | — | 70 | $197,444.00 | 0.62% |
Keith C. Regnante | Chief Financial Officer | $649,232.00 | — | 56 | $60,000.00 | 0.19% |
Esther Cho | Chief Legal Officer & Secretary | $634,192.00 | — | 37 | $80,000.00 | 0.25% |
Lorena Lerner | Chief Scientific Officer | — | — | 54 | $31,127.00 | 0.10% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
3
$44,700.00
Sells
9
$16.37M
Net Sentiment
$16.32M
Net selling
Most Active
BIENAIME JEAN JACQUES
3 transactions
1–10 of 12
Analysis
Insiders reported 3 buys worth $44,700.00 and 9 sells worth $16.37M over the last 12 months. That adds up to net selling of $16.32M. BIENAIME JEAN JACQUES was the most active insider with 3 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A5 analysts |
| Revenue | N/A | N/A | N/A | N/A6 analysts |
| Net Income | N/A | N/A | N/A | N/A6 analysts |
| EBIT | N/A | N/A | N/A | N/A6 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
MoonLake Immunotherapeutics
NASDAQ:MLTX
$1.38B
Absci Corporation
NASDAQ:ABSI
$1.06B
Ventyx Biosciences, Inc.
VTYX
$1.00B
Corvus Pharmaceuticals, Inc.
NASDAQ:CRVS
$1.00B
Olema Pharmaceuticals, Inc.
NASDAQ:OLMA
$862.12M
Rigel Pharmaceuticals, Inc.
NASDAQ:RIGL
$607.79M
CytomX Therapeutics, Inc.
NASDAQ:CTMX
$484.08M
REGENXBIO Inc.
NASDAQ:RGNX
$344.31M
Verastem, Inc.
NASDAQ:VSTM
$284.19M
Niagen Bioscience Inc
NASDAQ:NAGE
$274.77M
Who manages KROS?
Keros Therapeutics, Inc. (KROS) lists 4 active executives. The top listed executive is Jasbir S. Seehra, President, Chief Executive Officer & Director.
Are KROS insiders buying or selling?
Recent insider activity shows net buying of $39.73M.
Explore More
Continue the stock analysis
Jump to another research area for this company.